Current Investments
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | ALL
Destiny Pharma Ltd.
Bill Love, Brighton, UK,
http://www.destiny-pharma.demon.co.uk
Destiny Pharma Ltd focuses on the treatment and prevention of microbial infections. It is developing products which are effective against hospital “superbugs” such as methicillin-resistant Staphylococcus aureus (MRSA).
Diagnoplex Biosciences AG
Stavros Therianos, Lausanne, CH
Diagnoplex is leveraging its molecular platform capabilities to develop a colorectal cancer (CRC) screening test. Diagnoplex’s non-invasive CRC test, named “COLOX”, will be made available as a ready-to-use clinical laboratory kit.